Panel-negative strategy for suspected fusion-driven papillary thyroid carcinoma

Yoichiro Okubo1, Ikki Takada2, Mei Kadoya3

  • 1Kanagawa Cancer Center, Department of Pathology, 2-3-2 Nakao, Asahi-ku, Yokohama, Kanagawa, 241-8515, Japan. yoichiro0207@hotmail.com.

Thyroid Research
|June 6, 2026
PubMed
Summary

Molecular testing for thyroid nodules and papillary thyroid carcinoma (PTC) is crucial when results impact treatment. A new framework helps interpret limited test results, especially when suspicion for fusion-driven PTC persists, ensuring appropriate molecular testing.

Related Concept Videos